

PUBLIKATIONSVERZEICHNIS DR. JOHANNES KRÄMER

2019

von Scheidt F, Meier S, Krämer J, Apitz A, Siaplaouras J, Bride P, Kaestner M, Apitz C. **Heart Rate Response During Treadmill Exercise Test in Children and Adolescents With Congenital Heart Disease.** Front Pediatr. 2019;7:65-. [IF 2.35]

2018

Krämer J, Kreuzer F, Kaestner M, Bride P, von Scheidt F, Siaplaouras J, Latus H, Schranz D, Apitz C. **Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension.** Pediatr Cardiol. 2018;39:1115-1122. [IF 1.54]

Krämer J, Weidemann F. **Biomarkers for Diagnosing and Staging of Fabry Disease.** Curr Med Chem. 2018;25:1530-1537. [IF 3.18]

2017

Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F. **Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.** Nephrol Dial Transplant. 2017. Epub ahead of print. [IF 4.6]

2016

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E: **Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.** Orphanet J Rare Dis. 2016;29:88. [IF 3.3]

Seydelmann N, Liu D, Krämer J, Drechsler C, Hu K, Nordbeck P, Schneider A, Störk S, Bijmens B, Ertl G, Wanner C, Weidemann F: **High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.** J Am Heart Assoc. 2016;31:5. [IF 5.2]

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E: **Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.** Orphanet J Rare Dis. 2016;11:54. [IF 3.3]

2015

Krämer J, Bijnens B, Niemann M, Störk S, Ritter C, Ertl G, Wanner Ch, Weidemann F: **The Impact of Left Ventricular Geometry and Blood Pressure on the Fabry Cardiomyopathy.** PlosOne 2015;10:e0140627. [IF 3.3]

Krämer J, Nordbeck P, Störk S, Ritter C, Ertl G, Wanner C, Weidemann F: **Electrical Changes in Resting-, Exercise- and Holter-Electrocardiography in the Fabry-Cardiomyopathy.** J Metab Dis. 2015;27. Epub ahead of print. [IF 3.3]

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Brand SM, Wanner C, Weidemann F, Brand E: **Fabry patients after enzyme replacement therapy dose reduction and treatment switch – renal impairment after 2 year follow-up.** J Am Soc Nephro. 2015;27:952-62. [IF 8.0]

Weidemann F, Störk S, Sommer C, Üçeyler N, Ertl G, Wanner C, Krämer J: **Morbus Fabry.** Der Kardiologe. 2015;2:196-207.

Weidemann F, Niemann M, Ertl G, Wanner Ch, Krämer J: **The Fabry Cardiomyopathy - Diagnostic approach and current treatment.** Curr Pharma Des. 2015;21:473-8. [IF 3.3]

2014

Wagner M, Krämer J, Blohm E, Verghe D, Weidemann F, Breunig F, Wanner C: **Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease.** BMC Nephrology. 2014;15:188-196. [IF 1.5]

Krämer J, Niemann M, Störk S, Frantz S, Beer M, Ertl G, Wanner C, Weidemann F: **Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry Disease.** Am J Cardiol. 2014;115:895-900. [IF 3.2]

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero Gonzalez H, Sommer C, Üceyler N, Niemann M, Stoerk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner Ch, Brand E: **Fabry Patients after Enzyme Replacement Therapy Dose Reduction Versus Compound Switch: a Systematic Clinical Observation of Outcome and Risk of Three Therapeutic Options.** J Am Soc Nephro. 2014;25:837-49. [IF 8.0]

Drechsler C, Schmiedecke B, Niemann M, Schmiedecke D, Krämer J, Davydenko I, Emmert A, Pilz S, Obermayer-Pietsch B, Weidemann F, Breunig F, Wanner Ch: **Potential role of Vitamin D deficiency on Fabry cardiomyopathy.** J Inherit Metab Dis. 2014;37:289-95. [IF 4.1]

2013

Krämer J, Niemann M, Liu D, Hu K, Machann W, Beer M, Wanner Ch, Ertl G, Weidemann F: **2D Speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.** Eur Heart J. 2013;34:1587-96. [IF 14.7]
